Denmark recommends Lundbeck migraine treatment
![Photo: Thomas Borberg/Politiken/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14624242/q97p92/ALTERNATES/schema-16_9/20030404-145952-pf-2464x1388ma.jpg)
Late Wednesday evening local time, Lundbeck took the final step toward getting Vyepti (eptinezumab) authorized for general use in patients with chronic migraines in Denmark.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Denmark to pass verdict on Lundbeck's migraine drug
For subscribers
Lundbeck counts on employee growth despite economic turmoil
For subscribers